Evidence mapPaperPMID 40485683Full record

ArticleKidney international reports2025

Early Determination of Tacrolimus Concentration-Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation.

Christophe Masset, Marine Lorent, Clarisse Kerleau, Claire Garandeau, Aurélie Houzet, Simon Ville, Diego Cantarovich, Gilles Blancho, Magali Giral, Jacques Dantal and 1 more

Abstract read
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christophe MassetService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Marine LorentService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Clarisse KerleauService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Claire GarandeauService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Aurélie HouzetService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Simon VilleService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Diego CantarovichService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Gilles BlanchoService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Magali GiralService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Jacques DantalService de Néphrologie et Immunologie Clinique, Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Nantes DIVAT Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fast tacrolimus-metabolizing kidney transplant recipients (KTRs) (i.e., tacrolimus trough-level/total daily dose [C0/D < 1.05]) have poorer allograft function; however, their identification in a real-life setting is challenging. We investigated the reproducibility of tacrolimus metabolic status during the first months after transplantation and its association with long-term allograft outcomes. Methods: All KTRs between 2000 and 2019 with a functional allograft at 1 month and receiving tacrolimus in our center were included. Fast or slow tacrolimus metabolizers were classified according to the time spent with a C0/D < 1.05 (> 75% = High, < 25% = Low) at various time points posttransplantation. We first determined the earliest accurate time for patient categorization by investigating C0/D variability during the first months. Second, a multivariate cause-specific Cox model studying allograft outcomes was performed in groups identified by their status determined from the earliest accurate timepoint after transplantation. Results: Among 1979 patients included in the analysis, 2 months was the earliest accurate timepoint to determine High patients (85% of High patients identified at 2 months remained High long-term, Brier score = 0.06). Multivariate analysis revealed that High patients determined at 2 months ( Conclusion: C0/D is a simple and pragmatic tool capable of identifying patients at risk of rejection and allograft failure as early as the second month posttransplantation.

Indexed as

allograft survivalkidney transplantationtacrolimus toxicity

Identifiers

PMID40485683
PMCPMC12142798

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.